Rocket Pharmaceuticals Inc Danon Update Call Transcript
Welcome to the Rocket Pharmaceuticals Inc. Danon Update Webcast Conference Call. My name is John. I'll be operator for today's call.
(Operator Instructions) Please note, the conference is being recorded. And I will now turn the call over to Mayur Kasetty.
Good morning. This is Mayur Kasetty, Director of Business Development and Operations and Investor Relations lead at Rocket Pharmaceuticals. Thank you for joining us.
The purpose of this call is to share and discuss key updates on our ongoing Phase I clinical trial of RP-A501 in Danon disease, which includes data that is being presented in an e-poster at the ongoing American Heart Association 2021 Scientific Sessions.
Before we begin, I would like to briefly discuss the use of forward-looking statements on this conference call. Statements we make on this call may include statements which are not historical facts and are considered forward-looking within the meaning of the securities laws and which are usually identified by the use of words such as anticipates, believes,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
